<p><strong>Hepatic Effects</strong>: Risk of abnormal liver tests, hepatitis, hepatic failure; monitor hepatic function during therapy.<br />
<br />
<strong>Hypersensitivity</strong>: Anaphylaxis, including shock has been reported. Risk of infusion-related adverse reactions, possibly histamine-mediated, including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; to reduce occurrence, do not exceed a rate of infusion of 1.1 mg/minute.<br />
<br />
<strong>Risk of Neonatal Toxicity Associated with Polysorbates</strong>: Anidulafungin contains polysorbate 80, an inactive ingredient. Thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension and metabolic acidosis haves been reported in low-birth weight infants receiving high doses of polysorbate. Anidulafungin is not approved in pediatric patients younger than 1 month of age.<br />
<br />
<strong>Hereditary Fructose Intolerance (HFI)</strong>: Anidulafungin contains fructose. Risk of metabolic crisis with life-threatening hypoglycemia, hypophosphatemia, lactic acidosis, and hepatic failure. Obtain history of HFI symptoms in pediatric patients before Anidulafungin administration.</p>